Slide 1: Fourth Quarter & Full Year 2025 Earnings Presentation
Fourth Quarter & Full Year 2025 Earnings Presentation March 2, 2026 1
Slide 2: Legal Information
Legal Information CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Statements included in this presentation that are not historical in nature or do not relate to current facts are intended to be, and are hereby identified as, forward-looking statements for purposes of the safe harbor provid
Slide 3: Q4-25: Key Messages
Q4-25: Key Messages Revenue stabilization and execution of cost synergies demonstrate that cash flow breakeven performance is achievable in 2nd half of 2026 • Reported fourth quarter 2025 revenue of $43.9M and adjusted cash usage of $3M • Captured $74M of $85M cost synergy target Hitting key milesto
Slide 4: Synergies Leading to Cash Flow Breakeven in 2026
Synergies Leading to Cash Flow Breakeven in 2026 Q2 Q3 Q4 Q1 2025 2025 2025 2026 Pre-close cost Complete physical Implement one • Systems and Financial Major Milestones actions in consolidation manufacturing team integration commercial and Implement one commercial Combine Lab Services oper
Slide 5: Meaningful progress in Alzheimer's Disease Testing
Meaningful progress in Alzheimer's Disease Testing ENABLING PARTNERS OUR LAB • Continuing success in lab • Submitted FDA 510(k) in Jan’26 enablement with Single-Marker pTau 217 • 3 ongoing clinical utility studies • with the best Multi-Marker test (anticipated to complete in (pTau 217, Aβ42/40, GFAP
Slide 6: Scientific Validation Driving Adoption
Scientific Validation Driving Adoption Spatial Simoa Number of Drug Trial Projects (Simoa Only) Publications Biomarkers Instruments Lab Services 6,318 768 2,538 283 702 2,365 53.8 670 256 642 189 2,155 2370 134 5011 111 44.5 15.8 104 543 1,810 1439 63 1330 168 3,941 1733 1183 149 16.7 1,405 30.9 116
Slide 7: Q4'25 Results vs PYQ4
Q4’25 Results vs PYQ4 (in $M) Q4’25 Revenue Mix Q4 GAAP Q4 Non-GAAP Instruments 14% 2024 2025 2024 2025 Var % Consumables 52% Accelerator 19% Revenue 35.2 43.9 35.2 43.9 25% Other 15% Gross Margin $ 22.2 20.0 20.3 21.9 8% Gross Margin % 63.0% 45.7% 57.7% 50.0% -764 bps Q4’25 Revenue $23.0 Simoa Oper
Slide 8: FY'25 Results vs PYQ4
FY’25 Results vs PYQ4 (in $M) FY’25 Revenue Mix FY GAAP FY Non-GAAP Instruments 13% 2024 2025 2024 2025 Var % Consumables 54% Accelerator 19% Revenue 137.4 138.9 137.4 138.9 1% Other 15% Gross Margin $ 83.1 65.0 75.0 65.7 -12% Gross Margin % 60.5% 46.8% 54.6% 47.3% -726 bps FY’25 Revenue $74.8 Simoa
Slide 9: FY'25 Revenue – Comparative Information
FY’25 Revenue – Comparative Information As part of the acquisition of Akoya, the Company assumed a diagnostics development agreement, which had unfavorable terms, and was recorded as an off-market contract. In Q1 2026, Quanterix and this diagnostics customer terminated the agreement. To provide a me
Slide 10: 2026 Guidance
2026 Guidance Full Year Revenue: $169 to $174 million 0–3% revenue growth after the effect of a terminated diagnostics development agreement Gross Margin GAAP gross margin between 45 to 49% Adjusted gross margin (Non-GAAP) between 49% to 53% Anticipate cash flow breakeven in the 2nd half of 2026 Exi
Slide 11: Adjusted EBITDA (non-GAAP)
Adjusted EBITDA (non-GAAP) 11
Slide 12: Adjusted Cash Usage (non-GAAP)
Adjusted Cash Usage (non-GAAP) 12
Slide 13: Additional Non-GAAP Financial Measures
Additional Non-GAAP Financial Measures 13
Slide 14: Contact Us
Contact Us General inquiries 900 Middlesex Turnpike, Billerica, MA 01821 USA 617.301.9400 info@quanterix.com www.quanterix.com